ImmunityBio, Inc. retweeted
Big news for bladder cancer patients! FDA just expanded approval of Anktiva with BCG for adults with BCG-unresponsive, high-grade papillary-only NMIBC — the first treatment approved for this group. This is a first, and that matters. Evidence from a closely related form of bladder cancer supported the approval.
fda.gov/drugs/resources-info…
ImmunityBio, Inc. retweeted
Replying to @DrPatrick
@DrPatrick will join @Piper_Sandler Virtual Oncology Symposium on Oct 16, 1PM ET for a fireside chat on ImmunityBio’s clinical progress and vision for cancer immunotherapy.
immunitybio.com/immunitybio-…
Contact Piper Sandler for information about attending the symposium and accessing session recordings.
ImmunityBio, Inc. retweeted
Strong patient-centered care starts with listening.
Today, patients, caregivers, patient leaders, and urologic experts came together at our first Annual Patient & Caregiver Conference to share perspectives, learn from one another, and explore ways to strengthen the patient voice.
Through meaningful discussions on communication, health literacy, access to care, and collaboration, attendees identified opportunities to improve the experience of patients and families across the urologic community.
Thank you to everyone who participated and contributed to a day of thoughtful conversation, connection, and shared learning.
ImmunityBio, Inc. retweeted
What an honor to meet with President Erdogan today. Under his leadership Turkey will be the center of excellence for patients with cancer in the region.
President @RTErdogan, who is in New York for the 81st session of the United Nations General Assembly, received Dr. Patrick Soon-Shiong at the Turkish House.
ImmunityBio, Inc. retweeted
ImmunityBio Announces Exclusive Supply of Tokyo-172 BCG (ImmunoBladder) to Address 14 Year US Shortage Following Randomized Clinical Trial Comparing Tokyo to TICE Strain.
Learn more here: ir.immunitybio.com/news-rele…
@DrPatrick #AUA26
ImmunityBio, Inc. retweeted
WATCH: New approaches to fighting cancer are shifting focus toward boosting the immune system. Dr. Patrick Soon-Shiong explains how AI-engineered antibodies could redefine treatment.
ImmunityBio, Inc. retweeted
This is excellent! This video assesses /discusses Dr. Patrick Soon-Shiong (founder of ImmunityBio ( $IBRX) ) and the cancer treatment game-changer drug, Anktiva. A MUST WATCH AND SHARE WITH EVERYONE!!!
youtu.be/5QYPW3edX28?si=5JIE…
ImmunityBio, Inc. retweeted
A major step forward for treatment options in Saudi Arabia!
#SFDA has approved Anktiva for adult bladder cancer and lung cancer patients—marking approval for the world’s first IL-15 receptor superagonist.
sfda.gov.sa/en/news/5521532
ImmunityBio, Inc. retweeted

NewsNation@NewsNation25 Nov 2025
United States
United StatesConnected via WebAccount-level information, not a live location or per-post device.
What if everything we thought we knew about cancer was wrong? @ChrisCuomo sits down with @drpatrick on a breakthrough that will astound you — “Killing Cancer” Tonight at 10p/9C only on NewsNation. To find NewsNation on your screen: NewsNationNow.com
ImmunityBio, Inc. retweeted

NewsNation@NewsNation25 Nov 2025
United States
United StatesConnected via WebAccount-level information, not a live location or per-post device.
What if everything we thought we knew about cancer was wrong? @ChrisCuomo sits down with @drpatrick on a breakthrough that will astound you — “Killing Cancer” Tonight at 10p/9C only on NewsNation. To find NewsNation on your screen: NewsNationNow.com
ImmunityBio, Inc. retweeted
Papillary non-muscle invasive #BladderCancer treatment guidelines gap. @drpatrick @ImmunityBio joins @UroDocAsh @MDAndersonNews to discuss expanding ANKTIVA® (NAI) use to include papillary-only BCG-unresponsive bladder cancer.
📊 82% bladder preservation at 36 months
🧬 CIS & papillary disease share a mechanism
❗NCCN exclusion despite NEJM-level data
🎥 Watch now: > bit.ly/3ZmLy9J
ImmunityBio, Inc. retweeted
Recombinant BCG addressing #BladderCancer treatment shortages. @drpatrick @ImmunityBio joins @UroDocAsh @MDAndersonNews to discuss efforts to address BCG shortage with "supercharged" recombinant BCG, showing unprecedented efficacy & less toxicity. The FDA expanded access program makes an alternative supply widely available. #WatchNow > bit.ly/3RVXM5g
ImmunityBio, Inc. retweeted
Recombinant BCG addressing #BladderCancer treatment shortages. @drpatrick @ImmunityBio joins @UroDocAsh @MDAndersonNews to discuss efforts to address BCG shortage with "supercharged" recombinant BCG, showing unprecedented efficacy & less toxicity. The FDA expanded access program makes an alternative supply widely available. #WatchNow > bit.ly/3RVXM5g
ImmunityBio, Inc. retweeted
Protecting immune cells before radiation in #ProstateCancer treatment. @drpatrick @ImmunityBio and @UroDocAsh @MDAndersonNews discuss N-803 immunotherapy & its potential to protect immune cells before radiation. #WatchNow for insights into innovative cancer care > bit.ly/43uAutE
ImmunityBio, Inc. retweeted
Initial data shows 2 patients with near Complete Response & 100% disease control in first 5 patients. When the immune system is protected, CR in tumors difficult to treat in recurrent GBM is possible. GBM trial open at CSSIFM.org
Data for lung cancer next #WCLC25
ImmunityBio, Inc. retweeted
Recombinant BCG addressing #BladderCancer treatment shortages. @drpatrick @ImmunityBio joins @UroDocAsh @MDAndersonNews to discuss efforts to address BCG shortage with "supercharged" recombinant BCG, showing unprecedented efficacy & less toxicity. The FDA expanded access program makes an alternative supply widely available. #WatchNow > bit.ly/3RVXM5g
ImmunityBio, Inc. retweeted
30 Years and $3B Toward a Universal Cancer Fighter - Patrick Soon-Shiong
@drpatrick @ImmunityBio @bullishbruk @Rainmaker1973
oncodaily.com/drugs/patrick-…
#OncoDaily #Oncology #Cancer #Health #Medicine #MedX #MedEd #MedNews #ANKTIVA @CancerWorldmag
ImmunityBio, Inc. retweeted
Protecting immune cells before radiation in #ProstateCancer treatment. @drpatrick @ImmunityBio and @UroDocAsh @MDAndersonNews discuss N-803 immunotherapy & its potential to protect immune cells before radiation. #WatchNow for insights into innovative cancer care > bit.ly/43uAutE
ImmunityBio, Inc. retweeted
Reviewing Exciting Multi-Tumor Data from Patients on the Bioshield Platform - Pat Soon-Shiong
@drpatrick
oncodaily.com/voices/pat-soo…
#OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews





























